...
首页> 外文期刊>Analytical and bioanalytical chemistry >Targeted LC-MS/MS for the evaluation of proteomics biomarkers in the blood of neonates with necrotizing enterocolitis and late-onset sepsis
【24h】

Targeted LC-MS/MS for the evaluation of proteomics biomarkers in the blood of neonates with necrotizing enterocolitis and late-onset sepsis

机译:有针对性的LC-MS / MS,用于评估新生儿血液中的蛋白质组学生物标志物与坏死性小肠结肠炎和晚期败血症

获取原文
获取原文并翻译 | 示例
           

摘要

Late-onset sepsis (LOS) and necrotizing enterocolitis (NEC) are severe life-threatening conditions for neonates. Accurate, early diagnosis and timely initiation of treatment are crucial. Non-specific overlapping clinical signs along with the non-sensitive/specific diagnostic tools set obstacles to speedy, trustful diagnosis including differential diagnosis. The objective of this study was to evaluate the potential of targeted LC-MS/MS proteomics in identifying diagnostic biomarkers of NEC or LOS. We conducted a prospective case-control study evaluating serum proteomics profiles of 25 NEC, 18 LOS, and an equal number of matched control neonates, over three sampling points. Eighty-three concatemers and synthetic peptides belonging to 47 protein markers of the two diseases were selected after thorough literature search. A novel selected reaction monitoring (SRM), LC-MS/MS method was developed for their analysis and evaluation as potential biomarkers. Multivariate and univariate statistical analyses highlighted significant proteins in differentiating LOS and NEC neonates and diseased from controls. Moreover, panels of proteins were tested for their ability to distinguish LOS from NEC and controls. We suggest two panels of three proteins each, exhibiting very high diagnostic value for LOS and excellent diagnostic performance at the critical LOS-NEC differentiation, reaching an AUC ROC value close to 1 (0.999). These panels constitute a valuable starting point for further validation with broader cohorts of neonates, aiming to improve the clinical practice.
机译:晚期败血症(LOS)和坏死性小肠结肠炎(NEC)对新生儿的严重危及生命危及的条件。准确,早期诊断和及时的治疗起始至关重要。非特异性重叠临床符号以及非敏感/特定的诊断工具集障碍,以速度,可信赖的诊断,包括鉴别诊断。本研究的目的是评估靶向LC-MS / MS蛋白质组学的潜在鉴定NEC或LOS的诊断生物标志物。我们进行了一个预期案例对照研究,评估了25个NEC,18磅和相同数量的匹配控制新生儿的血清蛋白质组学曲线,超过三个采样点。在彻底的文献搜索后,选择了属于两种疾病的47个蛋白标记的八十三个联系人和合成肽。开发了一种新的选择反应监测(SRM),LC-MS / MS方法,用于分析和评估作为潜在的生物标志物。多变量和单变量统计分析突出显示了将LOS和NEC新生儿与对照区分中的显着蛋白质。此外,测试蛋白质面板的能力,以将LOS与NEC和对照区分开。我们建议两个三种蛋白的面板,在临界LOS-NEC分化下表现出极高的诊断价值和出色的诊断性能,达到接近1(0.999)的AUC ROC值。这些面板构成了具有更广泛的新生儿的进一步验证的有价值的起点,旨在改善临床实践。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号